Cognition Therapeutics Confirms FDA Path for Zervimesine in DLB Psychosis
CGTX has more than doubled off its 52-week low of $0.222.
Summary
Cognition Therapeutics reported a successful FDA meeting, establishing a clear path for its lead drug zervimesine to advance into a registrational study for dementia with Lewy bodies psychosis.
Key Events · Product Development and Regulatory · CGTX
-
FDA Meeting Completed
Cognition Therapeutics held a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026, to discuss zervimesine in dementia with Lewy bodies patients with psychosis.
-
Path Forward for Registrational Study
The company announced a productive discussion with the FDA, confirming a path forward for a registrational program for zervimesine (CT1812) in DLB patients with psychosis.
-
Awaiting Formal Minutes
Cognition Therapeutics expects to review the FDA's formal minutes regarding the meeting in June.
Analysis · CGTX · Life Sciences
Cognition Therapeutics announced a productive meeting with the FDA, confirming a path forward for a registrational study of zervimesine in dementia with Lewy bodies (DLB) psychosis. This positive regulatory update significantly de-risks the development of their lead candidate and moves the company closer to a pivotal trial, which is critical for a clinical-stage biopharmaceutical company. Investors will now await the formal FDA minutes in June for further details.
At the time of this filing, CGTX was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.5M. The 52-week trading range was $0.22 to $3.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.